Action plan for HTA implementation
| Action within 1–2 years | Action within 3–5 years | Actions from 6–10 years | |
|---|---|---|---|
| Capacity building |
| Increasing awareness of HTA among the public | Decide on the need for local academic programs (PhD or masters) implementation |
| HTA funding |
| Outsourcing with third parties might be needed with increased capacity for appraisal | Assessment of technologies with no interest to the manufacturer will be prioritized by the ministry of health and assessed according to importance |
| Legislation on HTA | Single national HTA unit under the umbrella of the MoH | Unit will expand with increasing scope of technologies | |
| Scope of HTA implementation | Start assessing innovative pharmaceuticals with high budget impact to support reimbursement decisions | Expand scope to medical devices and surgical interventions | Expand scope to prevention programs and revising HTA decisions |
| Decision criteria | Initially use 1–3x GDP per capita threshold value, apply multiple thresholds, and pilot MCDA in certain cases | Develop a CET for Oman, expand the use of MCDA | |
| Quality and transparency of HTA implementation | Recommendations only are published during the first 5 years | After 1 year of pilot testing, clear timelines will be established | Critical appraisal reports are published |
| Use of local data | Use available local data from electronic databases | Build local data warehouse | |
| International collaboration | Participation/hosting international training | Exchanging experience through Gulf Cooperation Council |
| Action within 1–2 years | Action within 3–5 years | Actions from 6–10 years | |
|---|---|---|---|
| Capacity building | Train the trainers programs Providing regular short courses for decision makers Inclusion of short courses in the residency program of healthcare professionals | Increasing awareness of HTA among the public | Decide on the need for local academic programs (PhD or masters) implementation |
| HTA funding | Public funding by the ministry of health will take the lead for the critical appraisal with minor submission fees from the private sector Assessment should be financed mainly by pharmaceutical companies | Outsourcing with third parties might be needed with increased capacity for appraisal | Assessment of technologies with no interest to the manufacturer will be prioritized by the ministry of health and assessed according to importance |
| Legislation on HTA | Single national HTA unit under the umbrella of the MoH | Unit will expand with increasing scope of technologies | |
| Scope of HTA implementation | Start assessing innovative pharmaceuticals with high budget impact to support reimbursement decisions | Expand scope to medical devices and surgical interventions | Expand scope to prevention programs and revising HTA decisions |
| Decision criteria | Initially use 1–3x GDP per capita threshold value, apply multiple thresholds, and pilot MCDA in certain cases | Develop a CET for Oman, expand the use of MCDA | |
| Quality and transparency of HTA implementation | Recommendations only are published during the first 5 years | After 1 year of pilot testing, clear timelines will be established | Critical appraisal reports are published |
| Use of local data | Use available local data from electronic databases | Build local data warehouse | |
| International collaboration | Participation/hosting international training | Exchanging experience through Gulf Cooperation Council |
Source(s): Authors work